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μ-opioid antagonist naltrexone, and the serotonin reuptake 
inhibitor sertraline. These drugs are recommended by evi-
dence-based guidelines as a stepwise therapeutic approach. 
Patients unresponsive to these drugs should be referred to 
specialized centers to receive experimental approaches 
such as UVB phototherapy, albumin dialysis, plasmapheresis 
or nasobiliary drainage. This review discusses pruritogen 
candidates in cholestasis, gives novel insights into the neu-
ronal signaling pathway of pruritus and summarizes evi-
dence-based treatment options for patients suffering from 
pruritus in cholestasis.  © 2014 S. Karger AG, Basel 
 Introduction 
 Chronic pruritus is a sensory phenomenon accompa-
nying a broad range of systemic disorders including 
metabolic and endocrine diseases, hematologic and 
lymphoproliferative disorders, solid tumors, and infec-
tious diseases  [1, 2] . In hepatobiliary diseases, pruritus 
particularly accompanies those disorders with choles-
tatic features  [3–5] . In these disorders, cholestasis may 
be caused by a pure hepatocellular secretory failure (he-
patocellular cholestasis), cholangiocellular cholestasis 
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 Abstract 
 Chronic pruritus is a burdensome feature of numerous he-
patobiliary disorders such as primary biliary cirrhosis, prima-
ry sclerosing cholangitis, cholangiocarcinoma, inherited 
forms of cholestasis and intrahepatic cholestasis of pregnan-
cy. Bile salts, μ-opioids, serotonin, histamine and steroids 
have been controversially discussed in the pathogenesis of 
cholestatic pruritus. However, for these substances neither a 
correlation with itch severity nor a causative link has ever 
been established. Recent findings indicate that the potent 
neuronal activator lysophosphatidic acid and autotaxin, the 
enzyme forming lysophosphatidic acid, may play a key ele-
ment in the pathogenesis of cholestatic pruritus. Serum ac-
tivity of autotaxin correlated with itch intensity and response 
to antipruritic treatment in patients with cholestatic pruri-
tus, but not other forms of pruritus. Autotaxin activity there-
by represents the first biomarker for pruritus and had a pos-
itive predictive value of 70% in differentiating cholestatic 
pruritus from other forms of pruritus. Treatment options for 
patients with cholestatic pruritus include the anion ex-
change resin colestyramine, the PXR agonist rifampicin, the 
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with intrahepatic bile duct damage or cholestasis due to 
obstruction of the intrahepatic or extrahepatic bile duct 
system  [3, 6] . Interestingly, the prevalence of pruritus 
varies considerably between these hepatobiliary disor-
ders. Pruritus is the defining symptom of women suffer-
ing from intrahepatic cholestasis of pregnancy (ICP)  [7] 
and is experienced by up to 70–80% of patients with pri-
mary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis at any time during the course of their disease 
 [8–11] . In contrast, pruritus is less frequently reported 
by patients with obstructive cholestasis  [12] , or chronic 
hepatitis C infections  [13–15] . Noteworthy, itch is not 
or only rarely associated with chronic hepatitis B infec-
tion, parenteral nutrition-induced cholestasis, biliary 
hamartomas, Caroli syndrome, congenital liver fibrosis, 
alcoholic or non-alcoholic fatty liver disease [(N)AFLD], 
or alcoholic or non-alcoholic steatohepatitis [(N)ASH] 
even if cholestasis is present  [16] .
 Clinical Picture 
 Although often undervalued by clinicians, pruritus 
represents a major burden of cholestatic patients and can 
dramatically reduce quality of life. Pruritus may be mild 
and tolerable, but does in some patients limit daily life 
activities, cause severe sleep deprivation resulting in las-
situde, fatigue, depressed mood and even suicidal sensa-
tion. In rare cases, intractable pruritus may become a pri-
mary indication for liver transplantation  [17–20] .
 One characteristic feature of cholestatic pruritus is its 
circadian rhythm with patient’s reporting the highest in-
tensity in the evening hours and early at night  [6] . A di-
urnal variation of itch intensity has been objectified by 
measuring the scratching intensity in PBC patients using 
piezo-film technology  [10] . Another specific feature is its 
localization at the limbs and in particular at the palms and 
soles, but cholestatic pruritus is often reported to be gen-
eralized  [10, 21] . Female cholestatic patients commonly 
report pruritus worsening during the progesterone phase 
of the menstrual cycle, in late pregnancy, and during hor-
mone replacement therapy  [6, 22] . In multivariate analy-
sis, serum alkaline phosphatase and the Mayo risk score 
were found to be independent indicators for the occur-
rence of pruritus in PBC patients  [23] . 
 In contrast to dermatological pruritus, primary skin 
lesions are not detectable in these patients; however, in-
tense scratching activity may cause secondary skin altera-
tions such as excoriations and prurigo nodularis  [24] . Al-
though secondary skin lesions may be difficult to discrim-
inate from primary skin disorders, if no scratch tools are 
used, the so-called ‘butterfly sign’ points to a non-derma-
tological cause of chronic pruritus. This sign is defined as 
unaffected skin at the upper patient’s back due to difficul-
ties to manually reach that part of the body. Furthermore, 
typical skin signs of chronic liver disorders such as jaun-
dice, spider naevi, palmar erythema or leukonychia may 
help to identify the underlying cause.
 Pathogenesis 
 In spite of the growing knowledge of receptors and 
pathways responsible for acute itch signaling in mice, rats 
and other species  [25–27] as outlined below, the respon-
sible ligands and receptors for itch sensation in human 
beings remain unsolved for most disorders associated 
with chronic pruritus  [28] . The pathogenesis of pruritus 
in cholestasis remains likewise enigmatic. Several poten-
tial itch-causing substances including bile salts, endoge-
nous μ-opioids, histamine, serotonin and steroids have 
been controversially discussed. However, for these sub-
stances neither a correlation between serum and/or tissue 
concentrations and itch severity nor a causative link have 
ever been established  [5, 23] . Thus, these substances rath-
er seem not to be direct itch-causing molecules, although 
some might modulate the neuronal signaling cascade 
leading to the desire to scratch. For detailed rationale in 
favor or against these substances, the reader is referred to 
previous reviews  [5, 29] . The current review highlights 
novel insights in the bile salt G-protein-coupled receptor 
TGR5 and lysophosphatidic acid (LPA) as well as the neu-
ronal itch signaling pathway.
 Potential Pruritogens 
 Clinical and experimental observations indicate that 
the itch-causing molecules in cholestasis accumulate in 
the systemic circulation as suggested by attenuation of 
pruritus after treatment with plasmapheresis or albumin 
dialysis. The pruritogens are secreted into bile as indi-
cated by rapid relief of severe, treatment-refractory pru-
ritus after nasobiliary drainage. Furthermore, the itch-in-
ducing substances are (biotrans)formed in liver and/or 
gut as indicated by effective treatment with the potent 
pregnane X receptor (PXR) agonist rifampicin. Finally, 
the pruritogens of cholestasis affect the endogenous opi-
oidergic and serotoninergic system  as suggested by mod-
erate antipruritic activity of μ-opioid antagonists and se-
lective serotonin reuptake inhibitors  [3, 5] . It was our hy-
pothesis that itch-causing molecules during cholestasis 
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accumulate in serum, which should be capable of activat-
ing neuronal cells. We therefore screened sera of chole-
static patients with and without pruritus for the capacity 
of neuronal activation. Indeed, in a human neuroblasto-
ma cell line sera of cholestatic patients caused a dose-de-
pendent transient rise in cytosolic free calcium concen-
trations  [30] . The main neuronal activator could be un-
raveled as a potent lipid mediator, LPA. LPA levels were 
increased in women with ICP compared to gestation-
matched women with uncomplicated pregnancy  [30] . In-
tradermal injection of LPA caused a dose-dependent 
scratching behavior in mice confirming a previous mouse 
study  [30, 31] .
 Extracellular LPA is mainly synthesized from its pre-
cursor molecule lysophosphatidylcholine (LPC) by the ly-
sophospholipase D, also named autotaxin (ATX)  [32, 33] . 
LPC is present in high micromolar concentrations in plas-
ma and LPA levels largely depend on the amount of ATX 
as shown in heterozygous mice (ATX +/– )  [34] . The en-
zyme ATX is the second member of the family of ecto-
nucleotide pyrophosphatases/phosphodiesterases (ENPP) 
and also entitled as ENPP2. The affinity of ATX for nucle-
otides is however much lower compared to lysophospho-
lipids  [35] . ATX plays a critical role in diverse physiologi-
cal conditions such as vascular and neuronal develop-
ment, during pregnancy or for lymphocyte migration. 
Furthermore, ATX influences several pathophysiological 
states including neuropathic pain, cardiovascular diseas-
es, pulmonary fibrosis, cancer development and forma-
tion of metastases  [36] . Our studies have added a role of 
ATX in cholestatic pruritus. Serum ATX activity and ATX 
protein content were markedly increased in sera of ICP 
women compared to gestation-matched pregnant con-
trols and in sera of cholestatic patients with compared to 
those without pruritus  [37] . Furthermore, in contrast to 
other putative pruritogens such as serum bile salt levels or 
serum μ-opioid activity, serum ATX activity correlated 
with the actual itch intensity in these patients  [37] . Also, 
the decline in ATX levels correlated with treatment effi-
cacy of several medicinal and invasive therapeutic inter-
ventions such as colesevelam, rifampicin, molecular ad-
sorbents recirculating system (MARS ® ) therapy and na-
sobiliary drainage  [38] . ATX activity again returned to 
higher levels when pruritus relapsed in patients weeks to 
months after cessation of MARS therapy or nasobiliary 
drainage  [38, 39] . Rifampicin was found to reduce ATX 
expression at the transcriptional level in human liver-de-
rived cell lines by a PXR-dependent mechanism, possibly 
explaining the strong antipruritic effect of rifampicin in 
clinical practice at least in part  [38] .
 Serum ATX activity was higher in patients with pruri-
tus of cholestasis compared to patients with pruritus due 
to chronic kidney disease, Hodgkin’s disease or atopic 
dermatitis  [38] . Autotaxin activity had a positive predic-
tive value of 70% in differentiating cholestatic pruritus 
from pruritus associated with atopic dermatitis, uremia 
and Hodgkin lymphoma. Thus, ATX represents the first 
biomarker for a chronic itch condition and might repre-
sent a useful diagnostic tool for those cases in whom 
chronic pruritus remains unclassified  [38] .
 These novel insights into the pathogenesis of chole-
static pruritus raise new questions. First of all, the source 
of the circulating ATX levels remains to be elucidated. 
Interruption of the enterohepatic circulation by nasobili-
ary drainage caused a rapid drop of circulating levels of 
ATX concomitant with relief of pruritus  [30, 38] . As ATX 
is not secreted into bile  [30] , a factor within the enterohe-
patic circulation may be responsible for the increased se-
rum ATX levels. Preliminary data from our laboratory 
point to the human small intestine as source of ATX [Bo-
lier et al., in preparation]. Which molecules are involved 
in the regulation of ATX gene expression is an unresolved 
question. In that regard, steroids may play a role as auto-
taxin gene expression was upregulated in the hippocam-
pus of ovariectomized rats upon treatment with estrogen 
 [40] . Intake of oral contraceptives was associated with in-
creased serum ATX levels in healthy female individuals 
[Kremer et al., in preparation]. Thus, steroids may par-
ticularly in pregnancy and ICP be responsible for in-
creased ATX levels. A further issue is the molecular 
mechanism of LPA-induced scratching behavior as out-
lined below.
 Bile salts have been implicated in the pathogenesis of 
cholestatic pruritus almost since their discovery  [5, 41] . 
Bile salts mediate their effects via the nuclear transcrip-
tion factor farnesoid X receptor (FXR) or the transmem-
brane G-protein-coupled receptor TGR5  [42] . Upon 
binding to these receptors, bile salts are capable of activat-
ing complex transcriptional networks and intracellular 
signaling cascades. Activation of FXR has proven various 
beneficial effects in different pathophysiological states in-
cluding cholestasis, liver fibrosis, non-alcoholic steato-
hepatitis and hepatocellular carcinoma  [42, 43] . The 
semisynthetic bile salt obeticholate (6-ethyl-chenodeoxy-
cholate) is a selective FXR ligand which is currently stud-
ied in clinical trials in patients with PBC and NASH  [44] . 
This drug exerted beneficial anticholestatic effects in 
PBC; however, it caused pruritus particularly at high dos-
es  [44] . The underlying mechanism remains elusive. Re-
cently, TGR5 was suggested to play a role in bile salt-me-
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diated pruritus and analgesia  [45] . TGR5 was detected in 
peptidergic neurons of mouse dorsal root ganglia, point-
ing out a possible role in sensory circuits. Indeed, intra-
dermal injection of high concentrations of the bile salts 
deoxycholate and lithocholate induced scratching behav-
ior which was attenuated in TGR5 –/– mice and augment-
ed in TGR5 transgenic mice  [45] . However, the applied 
concentrations of these hydrophobic bile salts were far 
beyond the pathophysiological levels observed in chole-
static disorders such as PBC or ICP which are associated 
with pruritus. These disorders are characterized by a de-
pleted deoxycholic acid (DCA) pool size  [46] with barely 
detectable concentrations of unconjugated DCA in se-
rum and bile. Still, other agonists of TGR5 such as neuro-
steroids might be capable of activating this receptor lead-
ing to itch sensation. Notably, progesterone has recently 
been shown to activate TGR5 in placental tissue in a dose-
dependent manner  [47] .
 Neuronal Itch Signaling 
 Itch sensation depends on a complex interplay of pru-
ritogens, their receptors on peripheral sensory nerve fi-
bers, intraspinal and cerebral neural pathways, as well as 
cerebral processing of the stimuli. The discovery of sen-
sory nerve fibers responsive to histamine but insensitive 
to certain algesic stimuli such as mechanical pain revolu-
tionized pruritus research 15 years ago  [48] . Still, these 
neurons can be activated by the algogen and TRPV1 ago-
nist capsaicin. Thus, the question remained whether sen-
sory neurons exist that exclusively mediate itch sensation. 
Only recently, a very elegant study presented evidence 
that a small subpopulation of sensory neurons expressing 
the Mas-related G-protein-coupled receptor subtype
A3 (MrgA3) could represent such neurons  [49] . Ablation 
of these MrgA3-positive neurons strongly attenuated 
scratching behavior in mice to most intradermally ap-
plied pruritogens. In mice lacking the TRPV1 channel, 
re-expression of TRPV1 only in MrgA3-positive neurons 
revealed that the algogen capsaicin largely caused scratch-
ing behavior but hardly any pain-related wiping  [49] . 
Thus, irrespective of the modality of activation, these 
neurons seem to induce itch sensation but no pain. Still, 
pain and itch signaling are closely intertwined processes: 
activation of pain neurons abrogates itch sensation, e.g. 
by scratching, cooling or heating of the skin  [1, 50] . An-
algetics may induce itch sensation, e.g. by epidural or in-
trathecal application of opioids or anesthetics  [51–53] . 
This can be explained by an itch circuitry which is under 
a tonic inhibitory control of mechanosensitive neurons 
( fig. 1 ). Evidence for such an inhibitory control was sup-
ported by the observation of spontaneous intense scratch-
ing behavior in mice lacking certain inhibitory, Bhlbh5- 
and Prdm8-expressing interneurons  [54, 55] . These in-
terneurons are believed to be activated by glutamate. 
Deletion of the glutamate transporter VGLUT2 caused 
increased spontaneous and induced scratching behaviors 
after application of pruritogens which underlined this hy-
pothesis  [56, 57] .
 Beside Mas-related G-protein-coupled receptor sub-
type A3 (MrgA3) which is activated by chloroquine  [58] , 
other receptors have been implicated in the onset of pru-
ritus. Among these are the MrgD for β-alanine  [59] , the 
μ-opioid receptor 1D for morphine-induced pruritus 
 [60] , endothelin-A receptor for endothelin-1  [61] , as well 
as the interleukin-13  [62] and interleukin-31 receptor 
 [63] . Activation of these receptors results in opening
of transient receptor potential (TRP) receptors such as 
the vanilloid-1 receptor (TRPV1) or ankyrin-1 channel 
(TRPA1) on sensory neurons  [49, 64] . Primary sensory 
neurons signal to the dorsal horn of the spinal cord where 
secondary neurons are activated by release of glutamate 
and neuropeptide natriuretic polypeptide b (Nppb)  [65] . 
Secondary neurons express natriuretic peptide receptor 
A (NprA, the receptor for Nppb) and were suggested to 
release gastrin releasing peptide (GRP) which activates 
the GRP receptor of a third neuron in the spinal cord 
( fig. 1 )  [65–67] . Ablation of either the NrpA or GRP re-
ceptor expressing neurons by intrathecal application of a 
toxin bound to the respective signaling molecule largely 
abolished scratching behavior after intradermal applica-
tion of various pruritogens  [65, 67] . Noteworthy, pain re-
sponses were unaltered after ablation of these neurons, 
indicating that a selective itch pathway exists on spinal 
cord level  [65, 67] .
 The molecular mechanisms of LPA-induced scratch-
ing behavior still remain to be elucidated. LPA is synthe-
sized by ATX and may act via at least six G-protein-cou-
pled receptors for LPA (LPA 1–6 )  [35, 68] . These receptors 
are present in various tissues including the nervous sys-
tem. LPA can induce neuropathic pain via LPA 1 , LPA 3 
and LPA 5 receptors  [69] . LPA was recently suggested to 
also directly activate the transient receptor potential 
vanilloid receptor subfamily V1 (TRPV1) and may there-
by mediate neuropathic pain  [70] . Intracellularly applied 
LPA activated TRPV1 considerably faster and stronger 
than extracellular LPA via an intracellular binding site
on TRPV1  [70] . As LPA contains a charged phosphate 
group, it cannot easily cross the plasma membrane and 
it remains to be shown how relevant this type of activa-
tion is with regard to extracellularly generated LPA. 
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Which LPA receptor and intracellular signaling pathway 
is required for LPA-induced pruritus warrants further 
investigation.
 Management 
 Current treatment recommendations for pruritus in 
cholestasis are based on only a few well-designed, ran-
domized, placebo-controlled trials and several cohort 
studies  [3] . The rationale for medical and interventional 
therapeutic approaches is (i) to remove the pruritogen(s) 
from the enterohepatic cycle by non-absorbable, anion 
exchange resins such as cholestyramine in mild pruritus 
or invasive interventions such as nasobiliary and transcu-
taneous drainage or external biliary diversion in desper-
ate cases; (ii) to alter the metabolism of the presumed 
pruritogen(s) in the liver and/or the intestine by inducers 
of the hepatic biotransformation machinery such as ri-
fampicin; (iii) to modulate central itch and/or pain sig-
naling by influencing the endogenous opioidergic and se-
rotoninergic system via μ-opioid antagonists and selec-
tive serotonin re-uptake inhibitors (SSRI), respectively, 
or (iv) to remove the potential pruritogen(s) from the sys-
temic circulation by invasive methods such as anion ab-
sorption, plasmapheresis or extracorporeal albumin di-
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 Fig. 1. Neuronal itch signaling. Simplified scheme of pain and itch 
signaling pathways from the peripheral to the central nervous sys-
tem and their interaction. Itch- and pain-causing molecules bind 
to specific receptors on sensory nerve endings in the epidermis or 
dermis. Among the established receptors for itch signaling are his-
tamine (H1, H4), serotonin (5-HT2), Mas-gene-related G-pro-
tein-coupled receptors (MrgA3, MrgC11, MrgD), endothelin (ET-
A), protease-activated receptor (PAR-4), and interleukin-31. 
These neurons also express transient receptor potential (TRP) re-
ceptors such as TRPV1 and TRPA1. Pruritus may also be initiated 
or potentiated by LPA receptors. Synaptic signal transmission 
from the peripheral sensory neuron to the secondary neuron in the 
dorsal horn of the spinal cord is mediated by glutamate (GLUT) 
and natriuretic polypeptide b (Nppb). Gastrin-releasing peptide 
(GRP) and GLUT may be involved in signal transmission to the 
tertiary neuron. The neuronal itch signaling pathway is under in-
hibitory control of the pain signals (as indicated by the Bhlhb5- 
and Prdm8-expressing interneurons). Pain sensation is similarly 
perceived by receptors on peripheral sensory neurons including 
neurokinin-1 (NK1) for substance P (SP) or protease-activated
receptor 2 (PAR-2) for proteases. Synaptic signal transmission 
from the peripheral sensory neuron to the secondary pain neurons 
and interneurons in the dorsal horn of the spinal cord is presum-
ably mediated by GLUT, SP, and calcitonin gene-related peptide 
(CGRP). 
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alysis if pruritus is intractable ( table 1 )  [3] . It should be 
noted that except for cholestyramine, all recommended 
drugs to treat pruritus of cholestasis have an ‘off label use’ 
character.
 Ursodeoxycholic acid (UDCA, 10–15 mg/kg/day) ex-
erts beneficial anticholestatic effects  [71] and represents 
therefore a baseline therapy for several cholestatic disor-
ders including PBC, cystic fibrosis-associated liver dis-
ease, pediatric cholestatic syndromes and ICP. Several 
case series reported UDCA to effectively attenuate pruri-
tus in some pediatric cholestatic disorders  [72–74] . In 
ICP, UDCA convincingly improved pruritus and serum 
liver tests in several randomized, placebo-controlled tri-
als and is regarded as first-line treatment  [3, 75] . This 
well-tolerated drug has been studied in several other 
chronic cholestatic disorders, but never with regard to 
itch as primary endpoint  [23, 76] .
 In pruritus of all other forms of intrahepatic cholesta-
sis and extrahepatic forms in which bile flow cannot be 
restored by invasive procedures, anion exchange resins 
are recommended as first-line treatment. Beneficial ef-
fects for cholestyramine have been reported in several 
small uncontrolled case series  [77–84] . Cholestyramine 
is recommended as a 4-gram sachet 1 h before and after 
breakfast and may be extended to 16 g/day. Resins 
should be taken at least 4 h prior to any other medication 
as they may interfere with their intestinal absorption. In 
a recent randomized, placebo-controlled trial, cole-
sevelam, which has a higher binding affinity for bile salts 
than cholestyramine, failed to be superior to placebo 
 [85] . Although cholestyramine may theoretically bind 
the ‘real’ itch-causing molecules more efficiently in the 
gut lumen than colesevelam, these results weaken the 
position of resins in the treatment recommendations 
 Table 1.  Therapeutic recommendations for the management of pruritus in cholestasis [3]
Approach Drug/therapya Dosage Evidence
ICP only UDCAb 10 – 15 mg/kg/day (p.o.) I/B1b
1st line Cholestyramine 4 – 16 g/day (p.o.) II-2/B1
2nd line Rifampicin 300 – 600 mg/day (p.o.) I/A1
3rd line Naltrexone 50 mg/day (p.o.) I/B1
4th line Sertraline 100 mg/day (p.o.) II-2/C2
Categories of evidencec
I Randomized controlled trials 
II-1 Controlled trials without randomization
II-2 Cohort or case-control analytic studies
II-3 Multiple time series, dramatic uncontrolled experiments
III Opinions of respected authorities, descriptive epidemiology
Evidence grading
A High quality: further research is very unlikely to change our confidence in the estimate of effect
B Moderate quality: further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate
C Low quality: further research is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate; any change of estimate is uncertain
Recommendation
1 Strong: factors influencing the strength of the recommendation included the quality of the evidence, 
presumed patient-important outcomes, and cost
2 Poor: variability in preferences and values, or more uncertainty; recommendation is made with less 
certainty, higher cost or resource consumption
 p.o. = Peroral.
a It should be noted that except for cholestyramine, all recommended drugs to treat pruritus of cholestasis 
have an ‘off label use’ character.
b Recommendation and evidence grade for ICP only.
c Categories of evidence according to the Grading of Recommendations Assessment Development and
Evaluation (GRADE) system.
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and underline the importance of randomized, placebo-
controlled trials.
 If resins are ineffective, the PXR agonist, rifampicin, is 
regarded as second-line treatment ( table  1 ). Four pro-
spective, randomized, placebo-controlled trials have 
proven the antipruritic efficacy of rifampicin  [86–89] . Ri-
fampicin is a safe short-term therapy of cholestatic pruri-
tus; however, hepatotoxicity may occur in up to 13% of 
patients after treatment for several weeks or months  [89] 
requiring the monitoring of serum transaminase levels at 
regular intervals. If rifampicin is ineffective within 2 
weeks, the μ-opioid antagonist naltrexone is recommend-
ed as third-line treatment. Naltrexone moderately im-
proved pruritus at doses of 25–50 mg/day in four small 
placebo-controlled trials  [90–93] . Adverse effects may in-
clude withdrawal-like reactions, particularly during the 
first days of therapy. Therefore, naltrexone should be ad-
ministered at low doses of 12.5 mg/day or intravenous 
infusion of naloxone followed by a stepwise dose increase. 
The selective serotonin uptake inhibitor sertraline (75–
100 mg/day) can be administered as fourth-line therapy. 
A single placebo-controlled crossover trial  [94] and a case 
series  [95] reported moderate antipruritic effects. Coad-
ministration of several drugs at the same time is not rec-
ommended due to the risk of drug-drug interactions. 
 Using this stepwise approach pruritus will improve in 
most patients. Experimental approaches such as UVB pho-
totherapy, albumin dialysis, plasmapheresis or nasobiliary 
drainage may be considered in those patients not adequate-
ly responding to standard care and should be performed in 
specialized medical centers. Only if all evidence-based and 
experimental therapies have failed liver transplantation can 
be regarded as the very last desperate therapeutic step.
 Conclusion 
 Cholestatic pruritus is a debilitating symptom of vari-
ous hepatobiliary disorders. We still scratch on the sur-
face of the complex molecular mechanisms responsible 
for this enigmatic symptom. Further insights into the sig-
naling cascade of itch sensation in cholestasis will open 
new avenues for the development of more effective treat-
ment strategies among which LPA receptor antagonists 
and ATX inhibitors may be of significance.
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